Pharmaceutical Among the political news last week, perhaps the most controversial of which was US President Donald Trump’s budget blueprint – a wish list of spending priorities for legislators to consider, which included a proposal to double the use fee charge that drugmakers pay to get their products through the regulatory process and a much criticized 20% cut in the budget for the National Institutes of Health. 19 March 2017